Moleculin Secures Mexican Patent for Lung-Targeted Annamycin Through 2040 — Moleculin Biotech, Inc.

Event summary

Moleculin Biotech received Patent No. 436849 from the Mexican Patent Office for its lung-targeted liposomal Annamycin, valid until 2040.
The patent strengthens the company's global IP portfolio for Annamycin, designed to target lung metastases and avoid multidrug resistance.
Annamycin is currently in the pivotal MIRACLE trial for relapsed/refractory AML, with long-term commercial potential.
The patent complements Moleculin's expanding international IP estate across multiple jurisdictions.

The big picture

Moleculin's latest patent win reinforces its strategy of building a robust IP moat around Annamycin, a differentiated anthracycline with potential applications beyond AML. The move aligns with broader biotech trends of securing international patent protection to maximize commercial lifespans. The patent's 2040 expiry provides long-term exclusivity, a critical factor as the company advances its pivotal trial and explores additional oncology indications.

What we're watching

IP Strategy: Whether Moleculin can sustain its global patent expansion to secure long-term exclusivity for Annamycin.
Clinical Progress: The pace at which the MIRACLE trial advances toward key milestones in relapsed/refractory AML.
Commercial Potential: How the lung-targeted formulation could expand Annamycin's development beyond hematologic malignancies.